Incyte Corporation

This early-stage trial tested a new drug called INCB040093, alone or combined with itacitinib, in 121 adults with B-cell cancers that had come back or stopped responding to treatment. The main goal was to find safe doses and check for side effects. Researchers also looked for sig…

This phase 2 study tested a drug called retifanlimab, which helps the immune system attack cancer, either alone or combined with other targeted drugs. It enrolled 206 women with advanced or metastatic endometrial cancer that had worsened after platinum-based chemotherapy. The goa…

This phase 2 study tested a drug called itacitinib in 4 people with myelofibrosis (a bone marrow disorder) who had already tried other treatments like ruxolitinib or fedratinib. The main goals were to check safety and see if it could shrink an enlarged spleen. The study was compl…

This Phase 3 trial tested whether combining pembrolizumab (an immunotherapy) with epacadostat (a drug that boosts the immune response) works better than standard drugs (sunitinib or pazopanib) for people with advanced kidney cancer that hasn't been treated before. The study enrol…

This phase 2 trial tested an oral drug called povorcitinib in 136 adults with chronic spontaneous urticaria (hives and itching lasting months) that standard antihistamines couldn't control. Participants took either povorcitinib or a placebo for 12 weeks to see if the drug reduced…

This phase 3 trial tested an oral drug called povorcitinib in 619 adults with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful abscesses. Participants received either the drug or a placebo for 12 weeks, followed by a 42-week extension. The mai…

This Phase 3 trial tested whether adding itacitinib (an anti-inflammatory drug) to standard steroids helps treat acute graft-versus-host disease (GVHD) in 439 people who had a stem cell transplant. GVHD occurs when donor immune cells attack the recipient's body. The study compare…

This study tested a drug called pemigatinib in 47 people with a rare type of blood cancer that has a specific gene change (FGFR1 rearrangement). The goal was to see if the drug could shrink or eliminate the cancer. The study found that some participants achieved a complete respon…

This study tested adding the targeted drug ruxolitinib to standard chemotherapy for children aged 1 to 21 with a high-risk form of B-cell acute lymphoblastic leukemia (ALL). The goal was to see if the combination could improve the number of children who remain cancer-free three y…

This study tested a new two-drug combination (itacitinib plus osimertinib) in 59 adults with advanced non-small cell lung cancer that has a specific EGFR gene mutation. The goal was to see if the combination is safe and helps shrink tumors. Participants received the drugs togethe…

This study tested a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 61 people with advanced melanoma or other solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drugs could s…

This study tested whether adding an experimental drug (epacadostat) to an immunotherapy (pembrolizumab) works better than standard chemotherapy for people with advanced head and neck cancer that has come back or spread. 89 adults took part. The main goal was to see how many patie…

This early-phase trial tested a new drug called INCA32459 in 46 people with advanced cancers that had spread. The main goals were to check safety, find the right dose, and see how the body handles the drug. It is too early to know if the drug works, but the results will guide fut…

This phase 3 trial tested the drug povorcitinib in 608 people with moderate to severe hidradenitis suppurativa, a chronic skin condition causing painful lumps and abscesses. Participants received either the drug or a placebo for 12 weeks, followed by a 42-week extension where eve…

This Phase 3 study tested whether adding the immunotherapy drug retifanlimab to standard chemotherapy (carboplatin and paclitaxel) helps people with advanced anal cancer that cannot be removed by surgery. The trial enrolled 308 participants worldwide. The main goal was to see if …

This study tracked 102 US adults with relapsed or refractory diffuse large B-cell lymphoma (a type of blood cancer) who were treated with a combination of tafasitamab and lenalidomide. The goal was to see how safe and effective this treatment is, especially for racial and ethnic …

This study tested a cream called ruxolitinib on 49 people with genital vitiligo, a condition that causes white patches on the genitals. Participants applied the cream twice daily for up to 48 weeks to see if it made the patches less noticeable. The goal was to improve appearance …

This study tested a cream called ruxolitinib on 204 people with prurigo nodularis, a skin condition causing intense itching and bumps. The goal was to see if the cream safely reduces itch better than a placebo cream. Participants applied the cream daily for 12 weeks, and research…

This study tested a cream called ruxolitinib on adults with moderate eczema (atopic dermatitis) who didn't get better with standard creams. 241 participants applied the cream or a placebo for 8 weeks. The main goal was to see if the cream could significantly improve eczema severi…

This study tested a cream called ruxolitinib in 190 adults with prurigo nodularis, a skin condition that causes intense itching and hard bumps. The goal was to see if the cream could safely reduce itch better than a cream with no active ingredient. Participants applied the cream …

This completed phase 1 study looked at how three common drugs—an antifungal (itraconazole), an antibiotic (rifampin), and acid reducers (esomeprazole, famotidine)—change the way a new experimental drug (INCB161734) moves through the body. Sixty-three healthy adults aged 18 to 55 …

This study looked at how a single dose of a drug called INCB123667 moves through and leaves the bodies of 9 healthy men. The drug was tagged with a tiny amount of radioactivity to track it in blood, urine, and stool. The goal was to understand how the drug is processed and elimin…

This completed Phase 1 study enrolled 5 healthy men aged 35-55 to see how a single oral dose of a radioactive form of the drug INCB099280 is absorbed, processed, and eliminated. Researchers measured radioactivity in urine, feces, and blood over time. The study does not test treat…

This early-stage study tested a new drug called INCB160058 in 137 healthy adults aged 18 to 55. The main goal was to check the drug's safety and how the body processes it, not to treat any disease. Participants took a single dose by mouth, and researchers monitored side effects a…

This study tested a new way to collect fluid from the skin using a tiny microneedle patch. Researchers compared samples from 20 healthy volunteers and people with eczema (atopic dermatitis) to see how much fluid could be collected and how well it was tolerated. The goal was to le…